Bio Med Sciences, Inc. has won $100,000 in research funds from the Life Sciences
Greenhouse of Central PA (LSGPA) to pursue “Improved Topical Treatments for
Hypertrophic Scars and Keloids”.
The LSGPA is a partnership between government, business and university professionals who are involved in assisting the commercialization of life science technologies. Ron Thiboutot, Ph.D. of LSGPA stated “Bio Med’s proposal withstood a rigorous review process and emerged from among a highly competitive field as one of exceptional quality in terms of both design and commercial potential.”
Mark Dillon, the President of Bio Med Sciences, commented, “Scars are not only a cosmetic issue which can impact a person’s self-esteem, severe scars can create serious disabilities. This is a particularly important issue with patients who survive massive burn injuries. We are proud to be involved in the development of solutions that can have a direct impact on the quality of people’s lives. Partnerships with dynamic medical professionals and funds from organizations like the LSGPA help us refine and create answers to these sorts of challenging problems.”
Bio Med Sciences currently manufactures and markets the Silon® and Oleeva® brands of scar management products for the professional market including burn centers and plastic surgeons. The same technology has just become available in the retail OTC market under the brand name Neosporin® Scar SolutionTM via a licensing arrangement with Pfizer Inc. This new project represents an opportunity to develop a “next generation” technology with potential impact in both the professional and OTC markets.
Work is expected to begin before the end of the first quarter of 2004 with a commercial product available in one or two years.
